Intrinsic LifeSciences

Executive Summary

Intrinsic LifeSciences is a private diagnostics company based in La Jolla, California, founded in 2007. The company focuses on the development and commercialization of research-use-only products for measuring hepcidin and erythroferrone (ERFE), key biomarkers in iron metabolism disorders. Their product portfolio includes ELISA kits such as the Intrinsic Hepcidin IDx™, Hepcidin Murine Compete™, and Primate Hepcidin Compete™, serving both human and preclinical animal models. Currently operating at a pre-clinical stage, Intrinsic LifeSciences aims to transition its assays from research tools to clinical diagnostics, targeting indications like anemia of chronic disease and iron deficiency. The company's expertise in hepcidin and ERFE quantification positions it as a niche player in the iron metabolism diagnostic space, with potential for partnerships with pharmaceutical firms developing iron-modulating therapies. However, limited public information on funding, revenue, or regulatory progress suggests an early-stage profile with moderate near-term commercial traction.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or CE marking for hepcidin diagnostic test35% success
• Q3 2026Strategic partnership with a large pharma company for biomarker testing services50% success